NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $3.05 +0.16 (+5.54%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.87▼$3.1250-Day Range$2.21▼$3.2252-Week Range$2.14▼$5.13Volume141,725 shsAverage Volume125,323 shsMarket Capitalization$97.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Anixa Biosciences alerts: Email Address Anixa Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.5% Upside$7.00 Price TargetShort InterestHealthy1.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 12 Articles This WeekInsider TradingAcquiring Shares$119,711 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.31 out of 5 starsMedical Sector582nd out of 936 stocksPharmaceutical Preparations Industry266th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.73% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 2.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 1.6 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.Search Interest17 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,711.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.43) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -8.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -8.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Anixa Biosciences Stock (NASDAQ:ANIX)Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More ANIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIX Stock News HeadlinesJuly 26 at 2:09 PM | finance.yahoo.comWe're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash WiselyJuly 25 at 7:10 AM | americanbankingnews.comAnixa Biosciences' (ANIX) "Buy" Rating Reaffirmed at HC WainwrightJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 24 at 2:05 PM | markets.businessinsider.comBuy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy TrialsJuly 23 at 10:56 PM | msn.comCW39 New Breast Cancer Vaccine undergoing clinical TrialsJuly 23 at 7:04 PM | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 23 at 7:04 PM | uk.finance.yahoo.comEXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T TherapyJuly 23 at 8:15 AM | prnewswire.comAnixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 17, 2024 | prnewswire.comAnixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine TechnologyJuly 15, 2024 | prnewswire.comAnixa Biosciences Announces $5 Million Share Repurchase ProgramJune 24, 2024 | prnewswire.comAnixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical TrialMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 21, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 21, 2024 | prnewswire.comAnixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 8, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 8, 2024 | msn.comAnixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccinesMay 8, 2024 | markets.businessinsider.comAnixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer VaccinesSee More Headlines Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/04/2024Today7/26/2024Next Earnings (Estimated)9/04/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+129.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,810,000.00 Net MarginsN/A Pretax Margin-5,174.29% Return on Equity-49.27% Return on Assets-45.55% Debt Debt-to-Equity RatioN/A Current Ratio14.40 Quick Ratio14.40 Sales & Book Value Annual Sales$210,000.00 Price / Sales464.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book4.07Miscellaneous Outstanding Shares32,010,000Free Float24,773,000Market Cap$97.63 million OptionableOptionable Beta0.89 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Amit Kumar Ph.D. (Age 60)CEO, Chairman & Co-Chair of CBAB Comp: $1.29MMr. Michael J. Catelani CPA (Age 57)MBA, President, COO, CFO & Corporate Secretary Comp: $788.83kMr. John Roop (Age 74)Senior Vice President of Engineering Comp: $275kDr. Pamela D. Garzone Ph.D. (Age 69)Chief Development Officer & Chair Breast Cancer Clinical Advisory Board Key CompetitorsEnzo BiochemNYSE:ENZPsychemedicsNASDAQ:PMDuniQureNASDAQ:QUREUroGen PharmaNASDAQ:URGNVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsArnold M BaskiesBought 5,000 shares on 7/26/2024Total: $15,450.00 ($3.09/share)Bank of New York Mellon CorpSold 14,000 shares on 7/26/2024Ownership: 0.228%Lewis H Titterton JrBought 405 shares on 6/13/2024Total: $1,093.50 ($2.70/share)Lewis H Titterton JrBought 330 shares on 6/10/2024Total: $858.00 ($2.60/share)Lewis H Titterton JrBought 10,738 shares on 6/7/2024Total: $27,059.76 ($2.52/share)View All Insider TransactionsView All Institutional Transactions ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $3.88 at the beginning of the year. Since then, ANIX shares have decreased by 21.4% and is now trading at $3.05. View the best growth stocks for 2024 here. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) issued its earnings results on Tuesday, June, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. Who are Anixa Biosciences' major shareholders? Top institutional shareholders of Anixa Biosciences include Bank of New York Mellon Corp (0.23%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL) and Akoustis Technologies (AKTS). This page (NASDAQ:ANIX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free anix Stock Alerts